Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer

Fondazione Policlinico Universitario Agostino Gemelli IRCCS80 enrolled

Overview

Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning. The study aims to apply radiomics for the prediction of response to neoadjuvant therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction

Interventions

CT scanRADIATION

All pre-operative CT scan collected

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with locally advanced stomach cancer undergoing neoadjuvant chemotherapy and gastrectomy between January 2005 and August 2022 Exclusion Criteria: * Siewert 1 tumors; * Patients who have received neoadjuvant with the addition of a biological drug; * Patients who have received radiotherapy; * Patients without staging CT scan or with insufficient image quality in terms of phases performed, pixel spacing, slide thickness (mandatorily: \> 5 mm) or artefacts.

Outcomes

Primary Outcomes

Use of radiomics

Apply radiomics for predicting response to neoadjuvant therapy.

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.